Selective cytotoxicity of chemical compounds to vascular endothelial cells is often beneficial for clinical applications including antivascular cancer therapy. In this study, the cytotoxicity of 35 organic compounds containing bismuth or antimony was evaluated based on the leakage of lactate dehydrogenase and morphologic observations in cultured bovine aortic endothelial cells and other cell types. The results indicate that only tris[2-(N,Ndimethylaminomethyl)phenyl]-bismuthane (TDPBi) had potent cytotoxicity to bovine aortic endothelial cells but not to bovine aortic smooth muscle cells and porcine kidney epithelial LLC-PK 1 cells; the compound exhibited moderate cytotoxicity to human fetal lung fibroblastic IMR-90 cells. Neither inorganic bismuth nor tris[2-(N,Ndimethylaminomethyl)phenyl]stibane, in which antimony substitutes for bismuth with the same organic structure as TDPBi, exhibited cytotoxicity to vascular endothelial cells, suggesting that the entire structure of TDPBi is required for selective cytotoxicity. The present data revealed that TDPBi has selective cytotoxicity to vascular endothelial cells, which may be applicable in antivascular cancer therapy.
INTRODUCTION
Since vascular endothelial cell damage is an important event in the progression of inflammation and atherosclerosis, 1, 2) prevention of the pathologic changes in vascular endothelial cells has focused on pharmacologic and toxicologic studies. On the other hand, endothelial cells are key targets in cancer therapy because they participate in the growth of tumor tissue through vasculogenesis and angiogenesis. Agents that exhibit selective cytotoxicity to vascular endothelial cells may induce apoptosis in the cells and/or inhibit tumor-associated angiogenesis. Thus the search for such agents will contribute to the development of anticancer drugs.
Metal(loid)-containing compounds have been used historically as medicines for several thousands of years, especially in Chinese traditional medicine. Recently, it has been revealed that several metalcontaining compounds exhibit anticancer activities. 3) Arsenic, antimony, and bismuth are classified as metalloids that belong to group V in the periodic table. Arsenic trioxide and antimony trioxide have been used in patients with acute promyerocytic leukemia the past decade. 4) A series of antimony (III) compounds with polydentate carboxylic acids shows antitumor activity in mice inoculated with S180 solid tumors. 5) Treatment with inorganic bismuth results in regression of gastric lymphoma caused by Helicobacter pylori 6) and reduction of the toxic side effects of cisplatin by tissue-specific induction of metallothionein. 7) In the present study, the cell type-dependent cytotoxicity of 35 bismuth-or antimony-containing organic compounds synthesized originally was investigated using a cell culture system to search for novel organometalloid compounds that exhibit selective cytotoxicity to vascular endothelial cells.
MATERIALS AND METHODS
Materials ---Vascular endothelial cells derived from bovine aorta, LLC-PK 1 cells from porcine kid-ney, and IMR-90 cells from human fetal lung were purchased from Dainihon Pharmaceutical (Osaka, Japan). Vascular smooth muscle cells derived from bovine aorta were a gift from Dr. Yasuo Suda (Kagoshima University Graduate School of Sciences and Engineering, Kagoshima, Japan). Dulbecco's modified Eagle's medium (DMEM) and ASF 301 medium were purchased from Nissui Pharmaceutical (Tokyo, Japan) and Ajinomoto (Tokyo, Japan), respectively. Fetal bovine serum (FBS) was obtained from MP Biomedicals (Irvine, CA, U.S.A.). Tissue culture dishes and plates were obtained from Iwaki (Chiba, Japan). Novel bismuth and antimony compounds were synthesized using the following method. Compounds 05, 06, 28, and 29 were prepared by the reaction of SbCl 3 were synthesized as described previously. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The lactate dehydrogenase (LDH) kit, bismuth nitrate, and other reagents were from Wako Pure Chemical Industries (Osaka, Japan). Cytotoxicity Assay ---Vascular endothelial cells, vascular smooth muscle cells, LLC-PK 1 cells, and IMR-90 cells were each cultured in DMEM supplemented with 10% FBS in 24-well culture plates at 37°C in a humid atmosphere of 5% CO 2 in air until confluence. The medium was discarded, and the cell layer was washed twice with serum-free ASF 301 medium. The cell layer was then incubated at 37°C for 24 hr in 0.25 ml of fresh serum-free ASF 301 medium with or without bismuth(III) nitrate (10, 20, or 50 µM), organobismuth, and organoantimony compounds (2, 5, 10, or 20 µM). After incubation, the conditioned medium was harvested, and an aliquot of the medium was used for the assay of LDH activity. The cell layer was washed with Ca, Mgfree phosphate-buffered saline and then fixed with methanol and stained with Giemsa. Statistical Analysis ---Data were analyzed for statistical significance using analysis of variance (ANOVA) and Bonferroni's multiple t-test. p-Values of less than 0.05 were considered to indicate statistically significant differences. Table 1 shows the organobismuth and organoantimony compounds of which the cytotoxicity was examined in the present study. There has been no information about the biological activities of these 35 compounds. First, the cytotoxicity of the compounds at 10 µM each to vascular endothelial and smooth muscle cells was investigated because it was reported that the sensitivity of these two cell types to heavy metals is different. 22) As shown in Fig. 1 , of the tested compounds, compounds 04, 07, 09, and 10 markedly increased the LDH activity leaked into the medium from vascular endothelial cells after 24-hr treatment, suggesting that these four compounds have strong cytotoxicity to vascular endothelial cells. Interestingly, of these four compounds, only compound 07 did not increase the LDH leakage in vascular smooth muscle cells. Morphologic observations agreed with the results of the LDH leak- age assay. Specifically, compounds 04, 09, and 10 destroyed the monolayer of both endothelial and smooth muscle cell layers, whereas only the endothelial cell layer was damaged by compound 07 (Fig. 2) . These results clearly indicate that compound 07, tris[2-(N,N-dimethylaminomethyl)phenyl]bismuthane (TDPBi), may exhibit selective cytotoxicity to vascular endothelial cells.
RESULTS
To confirm this hypothesis, the cytotoxicity of TDPBi to porcine kidney LLC-PK 1 cells and human fetal lung IMR-90 cells was determined by morphologic observations (Fig. 3) . No degenerative change was observed in LLC-PK 1 cells (Fig. 3A) , although a decrease in the cell number with necrotic changes was caused by TDPBi 10 µM and more in IMR-90 cells after 24-hr incubation (Fig. 3B) . It is suggested that fibroblastic IMR-90 cells as well as vascular endothelial cells are sensitive to TDPBi; however, the destruction of the monolayer in vascular endothelial cells (Fig. 2B ) was more marked than that in IMR-90 cells (Fig. 3B) .
To compare the sensitivity of vascular endothelial cells to TDPBi with that of other cell types including vascular smooth muscle cells, LLC-PK 1 cells, and IMR-90 cells, the dose-dependent effect of TDPBi on the leakage of LDH was investigated and compared (Fig. 4) . TDPBi changed the LDH leakage from neither vascular smooth muscle cells nor LLC-PK 1 cells. In contrast, the organobismuth compound markedly increased the leakage from vascular endothelial cells after 24-hr treatment. TDPBi also increased the LDH leakage from IMR-90 cells, although the cells were less sensitive to the compound than vascular endothelial cells. The results were consistent with the morphologic observations, supporting the hypothesis that TDPBi exhibits selective cytotoxicity to vascular endothelial cells. Table 2 shows the effects of inorganic bismuth(III) nitrate on the leakage of LDH from vascular endothelial and smooth muscle cells. The inorganic bismuth did not influence the LDH leakage in either cell type.
DISCUSSION
In the present study, we searched for bismuthor antimony-containing compounds that exhibit cell type-dependent cytotoxicity from among 35 organobismuth and organoantimony compounds. It was found that the organobismuth compound TDPBi has potent cytotoxicity particularly to vascular endothelial cells. When bismuth was replaced with antimony (i.e., compound 34), the cytotoxicity to vascular endothelial cells disappeared. In addition, inorganic bismuth had no cytotoxicity to vascular endothelial cells. Taking these results together, the selective cytotoxicity of TDPBi to vascular endothelial cells requires the entire bismuth-containing structure of the molecule.
Sensitivity to chemicals and heavy metals often depends on the cell type. For example, the sensitivity of vascular smooth muscle cells to cadmium cytotoxicity is markedly higher than that of other cell types including vascular endothelial cells, Chang liver cells, and LLC-PK 1 cells; the high sensitivity is mainly due to a higher accumulation of cadmium. 22) On the other hand, the present data showed that the sensitivity to TDPBi is markedly high in vascular endothelial cells, moderately high in fibroblastic IMR-90 cells, and very low in vascular smooth muscle cells and LLC-PK 1 cells. Although the mechanism by which TDPBi exhibits selective cytotoxicity to vascular endothelial cells is unknown, it is suggested that vascular endothelial cells may lack a protective mechanism against TDPBi and/or have mechanisms that amplify the cytotoxicity of TDPBi. Although the molecules that participate in the protection and the amplification are unclear, the cytotoxicity of tumor necrosis factor (TNF)-α may be a good model of cell type-dependent cytotoxic- ity. Like TDPBi, TNF-α exhibits potent cytotoxicity to vascular endothelial cells, although vascular smooth muscle cells, fibroblasts, and epithelial cells are resistant to cytokine-mediated cytotoxicity. [23] [24] [25] Although the mechanisms underlying endothelial cell death induced by TNF-α are not simple, it has been shown that nitric oxide 26, 27) and the product(s) of aldose reductase catalysis 28) may mediate the cytotoxicity. It remains to be determined whether TDPBi and TNF-α exhibit cytotoxicity to vascular endothelial cells through a common pathway.
The selective cytotoxicity of TDPBi to vascular endothelial cells appears to be one of the beneficial effects for anticancer drugs, 29) because the cytotoxicity may result in inhibition of angiogenesis and/or vasculogenesis in tumor tissue. In other words, it must be determined whether the vascular tissue in tumors is damaged by TDPBi. At the same time, it should be clarified whether TDPBi can induce tumor cell death and which type of tumor cells is sensitive to TDPBi. On the other hand, it is possible that there are some organobismuth or organoantimony compounds that can control vascular endothelial and smooth muscle cell functions through metallothionein induction. Metallothionein is a low molecular-weight, cysteine-rich protein that detoxifies the toxicity of heavy metals, 30) metabolizes essential trace elements, 31) and scavenges free radicals. 32) Since physiologic factors such as thrombin and cytokines can induce metallothionein in vascular cells, 33, 34) it has been hypothesized that the protein may play specific roles in vascular tissue, for example, scavenging endogenous vasodilating nitric oxide. Inorganic bismuth is a potent inducer of metallothionein in vascular endothelial cells. 35) Therefore some organometalloid compounds may induce metallothionein without exhibiting cytotoxicity.
In conclusion, the present data demonstrate that TDPBi is a unique compound that exhibits selective toxicity to vascular endothelial cells. We postulate that the study of this organobismuth compound can be the first step in the development of novel agents that target vascular endothelial cells. Further investigations will be necessary to clarify not only the effects of TDPBi on tumor-associated angionegesis/ vasculogenesis and tumor cell survival but also the procedures for controlling TDPBi effects. Such investigations will contribute to the clinical application of organobismuth compounds to vascular tissue.
